Drug repurposing for viral cancers: A paradigm of machine learning, deep learning, and virtual screening‐based approaches
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Cancer management is major concern of health organizations and viral cancers account for approximately 15.4% of all known human cancers. Due to large number of patients, efficient treatments for viral cancers are needed. De novo drug discovery is time consuming and expensive process with high failure rate in clinical stages. To address this problem and provide treatments to patients suffering from viral cancers faster, drug repurposing emerges as an effective alternative which aims to find the other indications of the Food and Drug Administration approved drugs. Applied to viral cancers, drug repurposing studies following the niche have tried to find if already existing drugs could be used to treat viral cancers. Multiple drug repurposing approaches till date have been introduced with successful results in viral cancers and many drugs have been successfully repurposed various viral cancers. Here in this study, a critical review of viral cancer related databases, tools, and different machine learning, deep learning and virtual screening‐based drug repurposing studies focusing on viral cancers is provided. Additionally, the mechanism of viral cancers is presented along with drug repurposing case study specific to each viral cancer. Finally, the limitations and challenges of various approaches along with possible solutions are provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rudin, C. (2019) · Nature Machine Intelligence · doi:10.1038/s42256-019-0048-x · Cited by 10,561 · cited 1×
“275,276 Additionally, the most persistent and major problem faced by AI methods is their black box nature 277 – 279 which hinders the researchers to visualize and explain what is going on inside these models.”
BackgroundThe cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092 · cited 5×
“TCGA and ICGC contain the information about viral cancers.”
BackgroundInfluentialDevelopment and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0897 · Cited by 6,763
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Activation of apoptosis signalling pathways by reactive oxygen species
Redza-Dutordoir, M., & Averill-Bates, D. A. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.09.012 · Cited by 3,731
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Pan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
A review of human carcinogens—Part B: biological agents
Bouvard, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., Ghissassi, F. E., Benbrahim-Tallaa, L., Guha, N., Freeman, C., Galichet, L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70096-8 · Cited by 2,935
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
An Overview of Overfitting and its Solutions
Ying, X. (2019) · Journal of Physics: Conference Series · doi:10.1088/1742-6596/1168/2/022022 · Cited by 2,352
International network of cancer genome projects
The International Cancer Genome Consortium (2010) · Nature · doi:10.1038/nature08987 · Cited by 2,299 · cited 5×
“The data made available in cancer projects interface is obtained from 49 ICGC sister projects 80 Moreover, processed, and labeled data files can be obtained from ICGC cancer project interface.”
BackgroundInfluentialDefinitions, methods, and applications in interpretable machine learning
Murdoch, W. J., Singh, C., Kumbier, K., Abbasi-Asl, R., & Yu, B. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1900654116 · Cited by 2,167 · cited 1×
“Till date, interpretable ML 127 – 129 and DL models 130,131 are open research area with dubious concepts behind the interpretability itself.”
BackgroundMulti-omics Data Integration, Interpretation, and Its Application
Subramanian, I., Verma, S., Kumar, S., Jere, A., & Anamika, K. (2020) · Bioinformatics and Biology Insights · doi:10.1177/1177932219899051 · Cited by 1,609
Chapter 1: HPV in the etiology of human cancer
Muñoz, N., Castellsagué, X., de González, A. B., & Gissmann, L. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.115 · Cited by 1,355
Artificial intelligence in COVID-19 drug repurposing
Zhou, Y., Wang, F., Tang, J., Nussinov, R., & Cheng, F. (2020) · The Lancet Digital Health · doi:10.1016/s2589-7500(20)30192-8 · Cited by 636 · cited 1×
“In this section ML, DL, and other approaches ‐ based drug repurposing approaches 24,171 – 173 are mentioned along with some examples.”
BackgroundOpening the black box: the promise and limitations of explainable machine learning in cardiology
Petch, J., Di, S., & Nelson, W. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2021.09.004 · Cited by 552
The Genotype-Tissue Expression (GTEx) Project
Carithers, L. J., & Moore, H. M. (2015) · Biopreservation and Biobanking · doi:10.1089/bio.2015.29031.hmm · Cited by 549
Sleire, L., Førde, H. E., Netland, I. A., Leiss, L., Skeie, B. S., & Enger, P. Ø. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.013 · Cited by 329
Oncogenic protein interfaces: small molecules, big challenges
Nero, T. L., Morton, C. J., Holien, J. K., Wielens, J., & Parker, M. W. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3690 · Cited by 312 · cited 1×
“…are variety of ML and DL approaches used such as drug ‐ target interaction (DTI) prediction, 187 – 191 drug – drug interaction, 78,192,193 target – target or protein – protein interaction (PPI), 194 – 197 and drug ‐ target ‐ disease 184 for drug repurposing in cancer and other related diseases.”
MethodMachine learning identifies candidates for drug repurposing in Alzheimer’s disease
Rodriguez, S., Hug, C., Todorov, P., Moret, N., Boswell, S. A., Evans, K., Zhou, G., Johnson, N. T., Hyman, B. T., Sorger, P. K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21330-0 · Cited by 299
Ye, Q., Hsieh, C.-Y., Yang, Z., Kang, Y., Chen, J., Cao, D., He, S., & Hou, T. (2021) · Nature Communications · doi:10.1038/s41467-021-27137-3 · Cited by 261
The transformational role of GPU computing and deep learning in drug discovery
Pandey, M., Fernandez, M., Gentile, F., Isayev, O., Tropsha, A., Stern, A. C., & Cherkasov, A. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00463-x · Cited by 255 · cited 2×
“Additionally, the unprecedented progress in computational power 23 and computational strategies of machine learning (ML) 4,24,25 and deep learning (DL) 26 – 30 in combination with NGS single ‐ cell RNA technologies have started to yield better results.”
BackgroundA genome-wide positioning systems network algorithm for in silico drug repurposing
Cheng, F., Lu, W., Liu, C., Fang, J., Hou, Y., Handy, D. E., Wang, R., Zhao, Y., Yang, Y., Huang, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10744-6 · Cited by 215
Cell Culture Based in vitro Test Systems for Anticancer Drug Screening
Kitaeva, K. V., Rutland, C. S., Rizvanov, A. A., & Solovyeva, V. V. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00322 · Cited by 142
Exploration of databases and methods supporting drug repurposing: a comprehensive survey
Tanoli, Z., Seemab, U., Scherer, A., Wennerberg, K., Tang, J., & Vähä-Koskela, M. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa003 · Cited by 131
Procko, E., Berguig, G. Y., Shen, B. W., Song, Y., Frayo, S., Convertine, A. J., Margineantu, D., Booth, G., Correia, B. E., Cheng, Y., et al. (2014) · Cell · doi:10.1016/j.cell.2014.04.034 · Cited by 127
Fu, L., Jin, W., Zhang, J., Zhu, L., Lu, J., Zhen, Y., Zhang, L., Ouyang, L., Liu, B., & Yu, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.006 · Cited by 83
The use of real-world data in drug repurposing
Park, K. (2021) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2021.29.e18 · Cited by 22 · cited 1×
“The data made available in cancer projects interface is obtained from 49 ICGC sister projects 80 Moreover, processed, and labeled data files can be obtained from ICGC cancer project interface.”
Method
Cited by
Revolutionizing healthcare: the role of artificial intelligence in clinical practice
Alowais, S. A., Alghamdi, S. S., Alsuhebany, N., Alqahtani, T., Alshaya, A. I., Almohareb, S. N., Aldairem, A., Alrashed, M., Bin Saleh, K., Badreldin, H. A., et al. (2023) · BMC Medical Education · doi:10.1186/s12909-023-04698-z · Cited by 3,146
AI-Driven Drug Discovery: A Comprehensive Review
Ferreira, F. J. N., & Carneiro, A. S. (2025) · ACS Omega · doi:10.1021/acsomega.5c00549 · Cited by 202
Brancato, V., Esposito, G., Coppola, L., Cavaliere, C., Mirabelli, P., Scapicchio, C., Borgheresi, R., Neri, E., Salvatore, M., & Aiello, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04891-8 · Cited by 106
“The effective organization of biomedical data in biobanking infrastructures is crucial to enable a comprehensive approach to clinical studies as well as the development of AI tools supporting clinical decision-making [131, 132].”
Background
Metadata
- Authors
- Ahmed, F., Kang, I. S., Kim, K. H., Asif, A., Rahim, C. S. A., Samantasinghar, A., Memon, F. H., & Choi, K. H.
- Venue
- Journal of Medical Virology
- Publisher
- Wiley
- Published
- 2023-03-31
- Volume
- 95
- Issue
- 4
- Pages
- e28693-e28693
- ISSN
- 0146-6615 (ISSN-L)
- 1096-9071
- OpenAlex
- W4353015244
- Cited by
- 69
- References
- 29
- FWCI
- 9.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.